



<p>Recipient Information</p> <p>1. Recipient Name PUBLIC HEALTH FOUNDATION ENTERPRISES, INC. 13300 CROSSROADS PKWY N STE 450 CITY OF INDUSTRY, CA 91746</p> <p>2. Congressional District of Recipient 31</p> <p>3. Payment System Identifier (ID) 1952557063A1</p> <p>4. Employer Identification Number (EIN) 952557063</p> <p>5. Data Universal Numbering System (DUNS) 082199324</p> <p>6. Recipient's Unique Entity Identifier L4EEW9SQX2F6</p> <p>7. Project Director or Principal Investigator Hyman Scott, MD hyman.scott@sfdph.org 628-217-7483</p> <p>8. Authorized Official Adam Abate aabate@helunahealth.org 562-222-7804</p>	<p style="text-align: center;">Federal Award Information</p> <p>11. Award Number 1R01MH143663-01</p> <p>12. Unique Federal Award Identification Number (FAIN) R01MH143663</p> <p>13. Statutory Authority 42 USC 241 42 CFR 52</p> <p>14. Federal Award Project Title PrEP Blueprint: Evaluating implementation of a PrEP Choice Blueprint on PrEP Uptake and Persistence</p> <p>15. Assistance Listing Number 93.242</p> <p>16. Assistance Listing Program Title Mental Health Research Grants</p> <p>17. Award Action Type New Competing</p> <p>18. Is the Award R&D? Yes</p> <table border="1" style="width:100%; border-collapse: collapse; margin-top: 10px;"> <tr> <th colspan="2" style="text-align: center;">Summary Federal Award Financial Information</th> </tr> <tr> <td colspan="2">19. Budget Period Start Date 03/05/2026 – End Date 11/30/2026</td> </tr> <tr> <td>20. Total Amount of Federal Funds Obligated by this Action</td> <td style="text-align: right;">\$659,242</td> </tr> <tr> <td> 20 a. Direct Cost Amount</td> <td style="text-align: right;">\$619,845</td> </tr> <tr> <td> 20 b. Indirect Cost Amount</td> <td style="text-align: right;">\$39,397</td> </tr> <tr> <td>21. Authorized Carryover</td> <td></td> </tr> <tr> <td>22. Offset</td> <td></td> </tr> <tr> <td>23. Total Amount of Federal Funds Obligated this budget period</td> <td style="text-align: right;">\$659,242</td> </tr> <tr> <td>24. Total Approved Cost Sharing or Matching, where applicable</td> <td style="text-align: right;">\$0</td> </tr> <tr> <td>25. Total Federal and Non-Federal Approved this Budget Period</td> <td style="text-align: right;">\$659,242</td> </tr> <tr> <td colspan="2"><hr style="border-top: 1px dashed black;"/></td> </tr> <tr> <td colspan="2">26. Project Period Start Date 03/05/2026 – End Date 11/30/2030</td> </tr> <tr> <td>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</td> <td style="text-align: right;">\$659,242</td> </tr> </table> <p>28. Authorized Treatment of Program Income Additional Costs</p> <p>29. Grants Management Officer - Signature Julie Marie Bergerud</p>	Summary Federal Award Financial Information		19. Budget Period Start Date 03/05/2026 – End Date 11/30/2026		20. Total Amount of Federal Funds Obligated by this Action	\$659,242	20 a. Direct Cost Amount	\$619,845	20 b. Indirect Cost Amount	\$39,397	21. Authorized Carryover		22. Offset		23. Total Amount of Federal Funds Obligated this budget period	\$659,242	24. Total Approved Cost Sharing or Matching, where applicable	\$0	25. Total Federal and Non-Federal Approved this Budget Period	\$659,242	<hr style="border-top: 1px dashed black;"/>		26. Project Period Start Date 03/05/2026 – End Date 11/30/2030		27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$659,242
Summary Federal Award Financial Information																											
19. Budget Period Start Date 03/05/2026 – End Date 11/30/2026																											
20. Total Amount of Federal Funds Obligated by this Action	\$659,242																										
20 a. Direct Cost Amount	\$619,845																										
20 b. Indirect Cost Amount	\$39,397																										
21. Authorized Carryover																											
22. Offset																											
23. Total Amount of Federal Funds Obligated this budget period	\$659,242																										
24. Total Approved Cost Sharing or Matching, where applicable	\$0																										
25. Total Federal and Non-Federal Approved this Budget Period	\$659,242																										
<hr style="border-top: 1px dashed black;"/>																											
26. Project Period Start Date 03/05/2026 – End Date 11/30/2030																											
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$659,242																										
<p>30. Remarks Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.</p>																											

Notice of Award



RESEARCH
Department of Health and Human Services
National Institutes of Health



NATIONAL INSTITUTE OF MENTAL HEALTH

SECTION I – AWARD DATA – 1R01MH143663-01**Principal Investigator(s):**

Hyman Scott, MD

Award e-mailed to: pdale@helunahealth.org

Dear Authorized Official:

The National Institutes of Health hereby awards a grant in the amount of \$659,242 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to PUBLIC HEALTH FOUNDATION ENTERPRISES in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award, including the "Terms and Conditions," is acknowledged by the recipient when funds are drawn down or otherwise requested from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Mental Health of the National Institutes of Health under Award Number R01MH143663. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please direct questions to the Federal Agency contacts.

Sincerely yours,

Julie Marie Bergerud
Grants Management Officer
NATIONAL INSTITUTE OF MENTAL HEALTH

Additional information follows

Cumulative Award Calculations for this Budget Period (U.S. Dollars)
Salaries and Wages

\$101,966

Fringe Benefits	\$35,622
Personnel Costs (Subtotal)	\$137,588
Materials & Supplies	\$1,500
Travel	\$9,840
Other	\$13,720
Subawards/Consortium/Contractual Costs	\$457,197
Federal Direct Costs	\$619,845
Federal F&A Costs	\$39,397
Approved Budget	\$659,242
Total Amount of Federal Funds Authorized (Federal Share)	\$659,242
TOTAL FEDERAL AWARD AMOUNT	\$659,242
AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$659,242

SUMMARY TOTALS FOR ALL YEARS (for this Document Number)		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$659,242	\$659,242
2	\$634,349	\$634,349
3	\$639,296	\$639,296
4	\$634,948	\$634,948
5	\$640,807	\$640,807

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

Payment System Identifier: 1952557063A1
Document Number: RMH143663A
PMS Account Type: P (Subaccount)
Fiscal Year: 2026

IC	CAN	2026	2027	2028	2029	2030
MH	8472592	\$659,242	\$634,349	\$639,296	\$634,948	\$640,807

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: 9A-ASGA / **OC:** 41021 / **Released:** 02/25/2026
Award Processed: 03/05/2026 04:43:43 PM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01MH143663-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – STANDARD TERMS AND CONDITIONS – 1R01MH143663-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 2 CFR Part 200.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 2 CFR Part 200. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to obtain a unique entity identifier (UEI) and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a UEI requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01MH143663. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Through acceptance of this award, recipient, and through implementation of this provision by recipient to each recipient investigator conducting work under this award, hereby grants to NIH a royalty-free, nonexclusive, and irrevocable right to reproduce, publish, or otherwise use for federal purposes and to authorize others to do so, all Author Accepted Manuscripts that result from this award, which includes making Author Accepted Manuscripts publicly available in PubMed Central upon the Official Date of Publication, in accordance with the 2024 NIH Public Access Policy.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of [Public Law 110-85](#)), the “responsible party” must register “applicable clinical trials” on the [ClinicalTrials.gov Protocol Registration System Information Website](#). NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

Recipients must administer the project in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age, and comply with applicable conscience protections. The recipient will comply with applicable laws that prohibit discrimination on the basis of sex, which includes discrimination on the basis of gender identity, sexual orientation, and pregnancy. Compliance with these laws requires taking reasonable steps to provide meaningful access to persons with limited English proficiency and providing programs that are accessible to and usable by persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. See <https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html> and <https://www.hhs.gov/>.

- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals, see <https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html> and <https://www.lep.gov>.
- For information on an institution’s specific legal obligations for serving qualified individuals with disabilities, including providing program access, reasonable modifications, and to provide effective communication, see <http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html>.
- HHS funded health and education programs must be administered in an environment free of sexual harassment; see <https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html>. For information about NIH’s commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH’s expectations are for institutions and the individuals supported on NIH-funded awards, please see <https://grants.nih.gov/grants/policy/harassment.htm>.
- For guidance on administering programs in compliance with applicable federal religious nondiscrimination laws and applicable federal conscience protection and associated anti-discrimination laws, see <https://www.hhs.gov/conscience/conscience-protections/index.html> and

<https://www.hhs.gov/conscience/religious-freedom/index.html>.

In accordance with the regulatory requirements provided at 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system that is found in [SAM.gov](https://sam.gov). Full reporting requirements and procedures are found in 2 CFR Part 200. This term does not apply to NIH fellowships.

Treatment of Program Income:

Additional Costs

Recipient is compliant with Title IX of the Education Amendments of 1972, as amended, 20 U.S.C. §§ 1681 et seq., including the requirements set forth in Presidential Executive Order 14168 titled Defending Women From Gender Ideology Extremism and Restoring Biological Truth to the Federal Government, and Title VI of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000d et seq., and Recipient will remain compliant for the duration of the Agreement.

- The above requirements are conditions of payment that go the essence of the Agreement and are therefore material terms of the Agreement.
- Payments under the Agreement are predicated on compliance with the above requirements, and therefore Recipient is not eligible for funding under the Agreement or to retain any funding under the Agreement absent compliance with the above requirements.
- Recipient acknowledges that this certification reflects a change in the government's position regarding the materiality of the foregoing requirements and therefore any prior payment of similar claims does not reflect the materiality of the foregoing requirements to this Agreement.
- Recipient acknowledges that a knowing false statement relating to Recipient's compliance with the above requirements and/or eligibility for the Agreement may subject Recipient to liability under the False Claims Act, 31 U.S.C. § 3729, and/or criminal liability, including under 18 U.S.C. §§ 287 and 1001.

Termination. This award is subject to the termination provisions at 2 CFR 200.340. Pursuant to 2 CFR 200.340, the recipient agrees by accepting this award that continued funding for the award is contingent upon the availability of appropriated funds, recipient satisfactory performance, compliance with the Terms and Conditions of the award, and may also otherwise be terminated, to the extent authorized by law, if the agency determines that the award no longer effectuates program goals or agency priorities in line with 2 CFR 200.340(a)(4).

SECTION IV – MH SPECIFIC AWARD CONDITIONS – 1R01MH143663-01

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

AWARD NOTICE:

This award has been made in response to the application submitted under the Notice of Funding Opportunity Announcement PAR-23-062 which can be referenced at:

<https://grants.nih.gov/grants/guide/pa-files/PAR-23-062.html>.

BUDGET/PROJECT PERIOD ADJUSTMENT:

This grant has been selected under the NIMH plan to redistribute grant workloads more evenly throughout the year. Consequently, the initial budget period reflects a 11/30/2026 end date. Subsequent budget periods will begin on 12/01 and will be for a 12-month duration. Although this grant will have a slightly shorter budget period this year, it is awarded the full 12-month level of funds for the budget period. If needed, additional time

may be requested at the end of the project period for a first no-cost extension through eRA Commons.

CONSORTIUM / CONTRACTUAL COSTS:

This award includes funds for consortium activity with:

- City/County of San Francisco
- UC, San Francisco
- University of Alabama, at Birmingham
- San Francisco AIDS Foundation

Each consortium is to be established and administered in accordance with the NIH Grants Policy Statement (<http://grants.nih.gov/grants/policy/nihgps/index.htm>). No foreign performance site may be added to this project without the written prior approval of the National Institute of Mental Health.

DATA SHARING PLAN:

This award is subject to the data sharing guidance outlined in NOT-MH-23-100 and can be found at: <https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-100.html>. The recipient will adhere to the resource and data sharing plan submitted by the AOR on 01/23/2026. Dissemination of study data will be in accordance with the accepted data sharing plan. **Please note that a statement of progress on the Sharing Plan must be included in the Research Performance Progress Report (RPPR) under section C.5 "Other Products and Resource Sharing."** Failure to adhere to the sharing plan as mutually agreed upon by the Recipient and the NIH/IC may result in Enforcement Actions as described in the NIH Grants Policy Statement.

Complete NIMH data sharing terms and conditions can be found at <https://nda.nih.gov/nda/sharing-regimen>. Instructions are available at <http://grants.nih.gov/grants/rppr/index.htm>. Complete guidelines on data sharing are available at <https://sharing.nih.gov/data-management-and-sharing-policy/about-data-management-and-sharing-policies/research-covered-under-the-data-management-sharing-policy#after>.

PARTICIPANT RECRUITMENT - MILESTONES:

Future NIMH support for this study is contingent upon adequate participant recruitment based on projected milestones as approved in the Recruitment Milestone Reporting system (RMR) on **02/09/2026**. It is expected that **0** of the **900** total projected participants will be recruited by **08/01/2026**. This tri-yearly recruitment report should be submitted electronically to NIMH after each milestone period of April 1, August 1 and December 1 at: <http://wwwapps.nimh.nih.gov/rmr/displayHome.action>. In the event that actual recruitment falls significantly below projected milestones, NIMH may consider withholding future support and/or negotiating an orderly phase-out of this study. Information regarding the NIMH Policy for the Recruitment of Participants in Clinical Research is available at: <https://grants.nih.gov/grants/guide/notice-files/NOT-MH-19-027.html>.

HUMAN SUBJECTS RESEARCH:

This award includes human subject research studies and must conform to the DHHS policies for the Protection of Human Subjects research, which are a term and condition of award. Human subjects research is covered by the 2018 Common Rule, and may not be initiated until the associated protocols have received IRB approval as specified in 45 CFR 46. Failure to comply with the terms and conditions of award may result in the disallowance of costs and collected data and/or additional enforcement actions as outlined in Section 8.5 of the NIH Grants Policy Statement.

SINGLE INSTITUTIONAL REVIEW BOARD (SIRB):

This grant includes the use of a single IRB, as outlined in the application dated 05/07/2025. As such, an Authorization (Reliance) Agreement must be established with

each site prior to conducting non-exempt human subjects research at that site. This agreement should describe the responsibilities of all parties and how communication between parties will occur--e.g., notification of the outcome of regulatory review, how protocol changes will be handled and who will be responsible for reporting of unanticipated problems and non-compliance. Please refer to <https://grants.nih.gov/policy/clinical-trials/single-irb-policy-multi-site-research.htm> for additional information and guidance.

GCP TRAINING:

NIH expects that all NIH-funded investigators and staff who are involved in the conduct, oversight, or management of clinical trials should be trained in Good Clinical Practice (GCP), consistent with principles of the International Conference on Harmonization (ICH) as stated in NOT-OD-16-148.

CLINICAL TRIAL DISSEMINATION PLAN:

The clinical trial(s) supported by this award is subject to the plan within the competing application dated 05/07/2025 submitted to NIH and the NIH policy on Dissemination of NIH-Funded Clinical Trial Information. It's required that the clinical trial(s) funded by this award will be registered in ClinicalTrials.gov not later than 21 calendar days after enrollment of the first participant and primary summary results reported in ClinicalTrials.gov, not later than one year after the completion date. The reporting of summary results is required by this term of award even if the primary completion date occurs after the period of performance.

CLINICAL TRIAL REQUIREMENTS:

This award is subject to additional certification requirements with each submission of the Annual, Interim, and Final Research Performance Progress Report (RPPR). The recipient must agree to the following annual certification when submitting each RPPR. By submitting the RPPR, the AOR signifies compliance, as follows: In submitting this RPPR, the SO (or PD/PI with delegated authority), certifies to the best of his/her knowledge that, for all clinical trials funded under this NIH award, the recipient and all investigators conducting NIH-funded clinical trials are in compliance with the recipient's plan addressing compliance with the NIH Policy on Dissemination of NIH-Funded Clinical Trial Information. Any clinical trial funded in whole or in part under this award has been registered in ClinicalTrials.gov or will be registered not later than 21 calendar days after enrollment of the first participant. Summary results have been submitted to ClinicalTrials.gov or will be submitted not later than one year after the completion date, even if the completion date occurs after the period of performance.

DATA AND SAFETY MONITORING:

This grant is subject to the clinical research policies outlined in NOT-MH-19-027. The recipient will adhere to the NIH (NIH GPS 4.1.15) and NIMH policies (NOT-MH-19-027) including appropriately providing adequate data and safety monitoring and timely reporting of key events as defined in the NIMH Reportable Events Policy. The level and frequency of human subject data and safety monitoring should always be commensurate with the risk and nature of the research.

Each RPPR submitted is expected to include, in Section **G.1 SPECIAL NOTICE OF AWARD TERMS AND FUNDING OPPORTUNITIES ANNOUNCEMENT REPORTING REQUIREMENTS**, a summary of key safety indices (e.g., cumulative rates of AEs/SAEs) during the reporting period and cumulatively over the course of the project; and a summary of any safety recommendations from the IRB reviews and any actions taken based on the recommendations.

OTHER SUPPORT TIME COMMITMENT:

Commitment overlap is not permitted and occurs when an individual's time commitment exceeds 100 percent (I.e., 12 person months), whether or not salary is requested. Therefore, no individual's time commitment may exceed 100 percent. Reductions in NIH support due to commitment overlap must be made in accordance with NIH policy as outlined in the NIH Grants Policy Statement.

Data Management and Sharing Policy: Applicable

This project is expected to generate scientific data. Therefore, the [Final NIH Policy for Data Management and Sharing](#) applies. The approved Data Management and Sharing (DMS) Plan is hereby incorporated as a term and condition of award, and the recipient shall manage and disseminate scientific data in accordance with the approved plan. Any significant changes to the DMS Plan (e.g., new scientific direction, a different data repository, or a timeline revision) require NIH prior approval. Failure to comply with the approved DMS plan may result in suspension and/or termination of this award, withholding of support, audit disallowances, and/or other appropriate action. See NIH Grants Policy Statement [Section 8.2.3](#) for more information on data management and sharing expectations.

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
DMS Costs	\$0	\$0	\$0	\$0	\$0

SPREADSHEET SUMMARY

AWARD NUMBER: 1R01MH143663-01

INSTITUTION: PUBLIC HEALTH FOUNDATION ENTERPRISES

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
Salaries and Wages	\$101,966	\$106,834	\$107,647	\$105,517	\$85,399
Fringe Benefits	\$35,622	\$37,322	\$37,606	\$36,862	\$29,834
Personnel Costs (Subtotal)	\$137,588	\$144,156	\$145,253	\$142,379	\$115,233
Materials & Supplies	\$1,500	\$1,000			\$1,000
Travel	\$9,840				\$6,000
Other	\$13,720	\$16,539	\$12,539	\$12,539	\$12,539
Subawards/Consortium/Contractual Costs	\$457,197	\$448,400	\$457,835	\$456,792	\$484,094
Publication Costs					\$1,500
TOTAL FEDERAL DC	\$619,845	\$610,095	\$615,627	\$611,710	\$620,366
TOTAL FEDERAL F&A	\$39,397	\$24,254	\$23,669	\$23,238	\$20,441
TOTAL COST	\$659,242	\$634,349	\$639,296	\$634,948	\$640,807

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	15%	15%	15%	15%	15%
F&A Cost Base 1	\$262,648	\$161,695	\$157,792	\$154,918	\$136,272
F&A Costs 1	\$39,397	\$24,254	\$23,669	\$23,238	\$20,441